Roberto Torres

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · Journal of Clinical Oncology · 2010 · 630 citations · Full text

Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial

Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · JNCI Journal of the National Cancer Institute · 2013 · 328 citations · Full text

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Aňa Lluch, Carlos H. Barrios, Laura Torrecillas et al. · Journal of Clinical Oncology · 2019 · 143 citations · Full text

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Poornima Saha, Meredith M. Regan, Olivia Pagani et al. · Journal of Clinical Oncology · 2017 · 141 citations · Full text

Quality Of Life, Surgical Oncology, Breast Oncology +18

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

Karin Ribi, Weixiu Luo, Jürg Bernhard et al. · Journal of Clinical Oncology · 2016 · 123 citations · Full text